Navigation Links
New Treatment for Autism 'Holds Promise'
Date:11/12/2009

SEATTLE, Nov. 12 /PRNewswire/ -- A new treatment for autism appears to normalize brain function, according to Nashville physician Fred S. Starr, MD, FAACAP, BCIA-EEG.

In addition to high serotonin levels, autistic children have a characteristically common "u" EEG pattern reflecting impaired brain function, particularly in areas of the brain responsible for social interaction, communication, speech and bonding.

However, Quantitative EEG's conducted by Dr. Starr on autistic children after three weeks on the medication Respen-A showed that the children's brain patterning changed to "normal" patterning. Starr says that behavioral improvement was also "evident". "Speech, interaction and social skills improved markedly in patients using Respen-A, and displays of frustration and anger markedly diminished," Starr said.

The theory behind the use of Respen-A was developed by private researcher Elaine DeLack, Stanwood, WA. Unlike theories that center on negative reaction to vaccinations, DeLack looked at exposure to a commonly used drug used during delivery, and at brain enzymes that affect the brain both at birth, and again as the child enters childhood.

DeLack's hypothesis (which can be viewed in slide show format at www.Neuro-Med.net) connects autism to the use of epidurals during childbirth. Epidurals were introduced into this country in the 1960's. By the mid-80's, 22 percent of women received an epidural during delivery. In the mid-90's, the number grew to 67%. Today, nearly 90% of women receive an epidural during pregnancy.

However, DeLack contends that it may not be the epidural procedure, but the drugs given in conjunction with the procedure, in combination with the drug Pitocin, that has contributed to increasing numbers in autism.

Pitocin crosses the placenta to the infant's system during childbirth. The drug requires adequate production of an enzyme found in the liver (CYP 3A4) in order to rid it from the body. If the infant has a genetic inadequacy of the CYP 3A4 enzyme (found more often to be lacking statistically in boys than girls), the drug's intensity could become elevated in the infant's system, and build with another naturally occurring neurotransmitter that plays a key role in brain development: the hormone Oxytocin.

Oxytocin builds naturally in the brain during the first 7 - 10 days of life, ensuring that nerve patterning develops as it should in the brain. Once Oxytocin levels reach a naturally predetermined level, the development of the brain's nerve system (HNS system) ceases.

DeLack theorizes that the addition of Pitocin into the bloodstream of infants without adequate CYP 3A4 genetic enzymes, causes brain development to "shut off" early, stunting crucial neuro-development.

DeLack hypothesizes that a second enzyme may explain why autism shows up in many children around the age of three. The enzyme MAO-A is essential in regulating serotonin levels in the brain. In the first years of life, MAO-A levels remain high, assisting brain function. The impact of MAO-A may, in fact, cover symptoms of brain impairment in infants and toddlers.

MAO-A levels diminish as the child ages - allowing serotonin levels to rise, impacting the areas of the brain associated with communication, speech, emotion and bonding. Respen-A curbs the level of serotonin in the autistic brain.

"We see promise in all of this," DeLack says. "Further study will determine if simple modification during childbirth could be all that is needed to stem the surging tide of autism," states DeLack. And for those who have autism? "Respen-A could give them a quality of life that they - and their parents - deserve."

Prescriptions for Respen-A require a daily calcium supplement. For further information about Respen-A, go to www.neuro-med.net

REPORTERS ARE WELCOME TO ATTEND SUNDAY'S SEMINAR AT PREECE AND TOFF SALON AT FRED SEGAL, 420 BROADWAY, SANTA MONICA, CALIFORNIA. TO RESERVE SPACE, CALL 877-963-3338.

Dr. Fred S. Starr may be reached at doc@5starrpsych.com

Elaine DeLack may be reached at elaine@edmsllc.com

SOURCE Neuro-Med.net


'/>"/>
SOURCE Neuro-Med.net
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
2. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
3. Imagenetix Announces Issuance of New U.S. Patent for the Prevention and Treatment of Periodontal Disease
4. ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases
5. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
6. Cancer Treatment Guidelines for Diverse Asian Economies Use Model Developed at Fred Hutchinson Cancer Research Center
7. Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections
8. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
9. Neuro Kinetics & Military Researchers in Push To Improve Diagnosis & Treatment of Combat Brain Injuries
10. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
11. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):